The PubMed entry documents a global, randomized, double-blind, controlled, phase III study titled ADDRESS that evaluated subcutaneous efgartigimod in combination with prednisone for moderate-to-severe pemphigus. The citation appears in the British Journal of Dermatology (Br J Dermatol), with Pascal Joly and colleagues named among the authors. The article is indexed under PMID 42723554 and DOI 10.1093/bjd/ljag199. The record lists the publication volume and pagination but, in the excerpt available here, does not include the article abstract text or the trial results.
Short, verifiable facts are present. The entry shows authorship, journal, DOI, and the collaborative ADDRESS Investigator Study Group roster. What is not present in this PubMed snapshot are the numerical outcomes, statistical analyses, or safety summaries that clinicians and guideline developers typically seek.
The page title explicitly describes the trial as a global, randomised controlled, double-blind, phase III investigation of subcutaneous efgartigimod administered with prednisone in patients with moderate-to-severe pemphigus. That designation implies randomized allocation and blinding, but the PubMed excerpt does not provide protocol details such as randomisation ratio, blinding method, inclusion/exclusion criteria, dosing schedule for efgartigimod, prednisone tapering strategy, treatment duration, or prespecified primary and secondary endpoints. The source text available here did not report those methodological details.
Readers are therefore informed only that the trial exists at a late-stage (phase III) level and that the investigational regimen paired a targeted agent with systemic corticosteroid therapy. The PubMed metadata does not state whether the trial included corticosteroid-sparing endpoints, patient-reported outcomes, autoantibody titres, time-to-repair measures, or other commonly used pemphigus efficacy metrics.
The ADDRESS Investigator Study Group is named and includes a broad international list of investigators and sites across multiple countries. The PubMed record gives a long collaborator roster—individual investigators are listed by name—and shows at least one institutional affiliation (Department of Dermatology, Rouen University Hospital, INSERM U1234 Normandie University). The collaborative scale reported suggests a multicentre design, but the excerpt did not enumerate participating countries, the number of sites, or coordinating centres.
The listing of collaborators does confirm a wide investigator pool and multidisciplinary authorship. The record thereby establishes academic and clinical engagement across dermatology centres, but stops short of operational trial detail such as site enrollment numbers or geographic enrollment distribution.
The visible PubMed content lacks core outcome data. The excerpt does not include: sample size or number randomized; the primary and secondary endpoints or their definitions; efficacy results (response rates, effect sizes, confidence intervals); corticosteroid exposure or sparing effects; safety and adverse-event frequencies; or statistical significance measures. The record also omits per-protocol or intention-to-treat population definitions, subgroup analyses, and duration of follow-up.
Because those metrics are not present in the provided PubMed snippet, no efficacy or safety claims can be extracted or summarized here without consulting the full Br J Dermatol article. The source did not report them in the section available for this summary.
Clinicians will reasonably ask: Did subcutaneous efgartigimod plus prednisone improve disease control versus prednisone alone or placebo? Was there a meaningful corticosteroid-sparing effect? What was the safety profile and were there new safety signals? How large was the trial, and were results consistent across pemphigus subtypes? The PubMed excerpt does not answer any of these.
To resolve these questions, consult the full-text Br J Dermatol publication referenced by DOI 10.1093/bjd/ljag199 or access the article through institutional subscriptions or clinical trial registries that may host the protocol and outcome data. The PubMed page provides the citation and collaborator list needed to locate the full report but does not substitute for the trial manuscript itself.
Limitations noted from this source: the available PubMed entry contains bibliographic and authorship details but omits abstract-level and in-text trial data in the excerpt provided. That omission prevents summary of efficacy, safety, statistical analyses, or predefined endpoints. The next step for clinicians and investigators wishing to interpret ADDRESS trial results is direct review of the Br J Dermatol article or associated clinical-trial registry entries, which should contain the trial methodology, endpoints, numerical outcomes, adverse-event summaries, and the study team’s interpretation of the findings.